Small interfering RNA for regulating and controlling barrier function of cell intestinal epithelial cells, overexpression vector and application of overexpression vector

By designing interfering RNA and overexpression vectors for the SLC26A3 gene, regulating the barrier function of intestinal epithelial cells, the problem that the existing technology failed to effectively regulate the SLC26A3 gene was solved, and significant changes in the barrier function of intestinal epithelial cells were achieved, which was a metabolic disorder and Treatment of IBD provides new approaches.

CN118910056APending Publication Date: 2024-11-08INSTITUTE OF ANIMAL SCIENCES OF CHINESE ACADEMY OF AGRICULTURAL SCIENCES
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411149980.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art has failed to effectively target and regulate the SLC26A3 gene to destroy or enhance the function of intestinal epithelial cell barrier, resulting in a continued increase in the prevalence of metabolic disorders and related diseases.

Method used

Provide interfering RNA and overexpression vectors for the SLC26A3 gene, targeting interfering or overexpressing the SLC26A3 gene through small interfering RNA (si-SLC26A3-1), regulating the barrier function of pig intestinal epithelial cells, and using fluorescence quantitative PCR and Western Blotting to detect related Genes and protein expression levels to evaluate the integrity of the intestinal epithelial cell barrier.

Benefits of technology

It has achieved significant reduction or enhancement of barrier function of intestinal epithelial cells, providing a basis for building disease models and therapeutic targets, and based on the anatomical and genetic similarity between pigs and humans, it has laid the foundation for the construction of IBD models and targeted treatments, and demonstrated High interference efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention belongs to the technical field of animal genetic engineering, and particularly relates to a small interfering RNA for regulating and controlling the barrier function of cell intestinal epithelial cells, an overexpression vector and application of the overexpression vector. The small interfering RNA provided by the invention is named si-SLC26A3-1, and after a solute-related vector 26A3 gene SLC26A3 is interfered by using the small interfering RNA, mucoprotein, tight junction protein and the like secreted by intestinal epithelial cells are remarkably reduced, which indicates that the barrier function of the intestinal epithelial cells is damaged. After cells are transfected by using the overexpression vector, mucoprotein, tight junction protein and the like secreted by intestinal epithelial cells are remarkably up-regulated, which indicates that the barrier function of the intestinal epithelial cells is enhanced. The small interfering RNA and the overexpression vector provided by the invention can regulate and control the barrier function of the epithelial cells of the pig intestines, and a feasible method is provided for construction and targeted therapy of IBD models of pigs and people based on the similarity of the pigs and the people in the aspects of anatomy, physiology, heredity and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of animal genetic engineering, and specifically relates to using the pig SLC26A3 gene as a target gene for regulating the barrier function of intestinal epithelial cells, and provides the application of small interfering RNA interfering with the SLC26A3 gene and an overexpression vector overexpressing the SLC26A3 gene. Background Art

[0002] The prevalence of metabolic diseases such as obesity is increasing rapidly worldwide. Metabolic disorders lead to dysfunction of related tissues and organs. Among them, necrotizing colitis, inflammatory bowel disease, etc. not only cause intestinal metabolic disorders, but also affect the health of the body through changes in intestinal metabolites and nutrient absorption. The intestine not only has multiple functions such as food digestion, nutrient absorption and hormone secretion, but also as an organ containing a large number of immune cells, it is widely involved in immune regulation and maintenance of metabolic homeostasis. Intestinal function is achieved through the synergistic action of multiple cells, including epithelial cells, interstitial cells and immune cells. The mechanical barrier in the intestine is formed by epithelial cells, among which the mucus secreted by goblet cells is responsible for forming the chemical barrier of the intestine. The mucus layer of the intestine separates enterocytes from bacteria in the lumen, and the destruction of the mucus barrier causes microorganisms to penetrate and contact epithelial cells. Invading microorganisms promote the recruitment of immune cells and the secretion of proinflammatory cytokines, leading to damage to epithelial cells. The loss of intestinal barrier integrity is believed to lead to uncontrolled immune responses or allow unlimited invasion of microbiota, leading to various diseases, including metabolic disorders such as obesity and diabetes. Therefore, research targeting intestinal barrier integrity holds promise for preventing and treating metabolic disorders.

[0003] Solute-related carrier 26A3 (SLC26A3) is a member of the SLC26 sulfate permeation / anion transporter family. The protein encoded by this gene is a key Cl--HCO3- exchange protein in the intestinal epithelial luminal membrane, with a predicted molecular weight of 85 kDa. It is mainly expressed in the apical membrane of colonic epithelial cells and less expressed in the jejunum and ileum. As an anion exchanger, SLC26A3 plays multiple functions in the intestine. Studies have found that the absence of SLC26A3 causes reduced Cl- and fluid absorption in the small intestine. In addition, when SLC26A3 is lacking in the gastrointestinal tract of mice, HCO3- secretion is significantly reduced. Compared with normal mice, SLC26A3 knockout mice show high postnatal mortality, significantly reduced serum Na+ and Cl- concentrations, growth retardation, renal failure and increased diarrhea. SLC26A3- / - mice occasionally suffer from rectal prolapse. SLC26A3 can promote the absorption of short-chain fatty acids in the large intestine and also mediate NO3- transport.

[0004] The regulation of SLC26A3 mainly includes regulation at the transcriptional, post-transcriptional and post-translational levels. At the transcriptional level, studies have found that hepatocyte nuclear factor 4 regulates the activity of the SLC26A3 gene promoter in human colon cells LS174T; Singla et al. found that lysophosphatidic acid treatment of Caco2 cells can stimulate the mRNA expression and promoter activity of the SLC26A3 gene; Kumar et al. found that tumor necrosis factor-α downregulates SLC26A3 in intestinal epithelial cells by activating NF-κB; there is a correlation between TNF-α and SLC26A3 expression, and NF-κB mediates the reduction of SLC26A3 in Caco2 cells induced by TNF-α; interferon-γ (IFN-γ) may reduce the expression of SLC26A3 through the JAK-STAT pathway; all-trans retinoic acid (ATRA) can also increase the activity of the SLC26A3 promoter, which is dependent on the retinoic acid receptor-β / hepatocyte nuclear factor-1β pathway. At the post-transcriptional level, a variety of miRNAs targeting the SLC26A3 gene have been discovered, which play an important role in the synthesis of the SLC26A3 gene. At the post-translational level, an important regulatory region of SLC26A3 is the PDZ domain, located at the C-terminus of the protein, through which SLC26A3 is recruited with other transporters, thereby mediating the interaction between proteins.

[0005] The prior art has not reported small interfering RNA that targets the SLC26A3 gene to regulate the barrier function of intestinal epithelial cells and the nucleotide sequence that overexpresses the SLC26A3 gene. Summary of the invention

[0006] The first purpose of the present invention is to use the solute-related carrier 26A3 gene SLC26A3 as a target gene to regulate the barrier function of porcine intestinal epithelial cells.

[0007] The second object of the present invention is to provide interference with the solute-related carrier 26A3 gene SLC26A3 to disrupt the barrier function of intestinal epithelial cells.

[0008] The third object of the present invention is to provide overexpression of the solute-related carrier 26A3 gene SLC26A3 to enhance the barrier function of intestinal epithelial cells.

[0009] To achieve the above object, the technical solution of the present invention is as follows: In a first aspect, the present invention provides a small interfering RNA of the solute-associated carrier 26A3 gene SLC26A3, the small interfering RNA is named si-SLC26A3-1, and the nucleotide sequence of the si-SLC26A3-1 is shown in SEQ ID NO.4 and SEQ ID NO.5.

[0010] The target gene of the small interfering RNA provided by the present invention is the solute-related carrier 26A3 gene SLC26A3, and the nucleotide sequence of the target gene is shown in SEQ ID NO.1.

[0011] Specifically, the present invention prepares small interfering RNA for the SLC26A3 gene, transfects porcine small intestinal epithelial cells IPEC-J2, and silences the solute-related vector 26A3 gene SLC26A3. After 48 hours of small interfering RNA transfection of porcine small intestinal epithelial cells IPEC-J2, the siRNA interference efficiency is evaluated. At the same time, fluorescent quantitative PCR is used to detect the expression levels of MUC2, MUC13, TFF3, OCLN, CLDN3, E-cadherin and SLC15A1 genes related to the barrier function of intestinal epithelial cells; and Western Blotting is used to detect the protein expression levels of MUC2, MUC13 and OCLN. The results show that the expression of mucin secreted by intestinal epithelial cells and intestinal epithelial cell tight junction proteins is significantly reduced, which has the effect of destroying the barrier function of intestinal epithelial cells and can be used to construct disease models.

[0012] The present invention uses the solute-related carrier 26A3 gene SLC26A3 shown in SEQ ID NO.1 as a target, and designs four small interfering RNAs, namely si-SLC26A3-1 (sense nucleotide sequence SEQ ID NO.4 and antisense nucleotide sequence SEQ ID NO.5), si-SLC26A3-2 (sense nucleotide sequence SEQ ID NO.6 and antisense nucleotide sequence SEQ ID NO.7), si-SLC26A3-3 (sense nucleotide sequence SEQ ID NO.8 and antisense nucleotide sequence SEQ ID NO.9), si-SLC26A3-4 (sense nucleotide sequence SEQ ID NO.10 and antisense nucleotide sequence SEQ ID NO.11), and a control group si-NC (sense nucleotide sequence SEQ ID NO.2 and antisense nucleotide sequence SEQ ID NO.3). It was finally found that si-SLC26A3-1 had the highest interference efficiency.

[0013] In a second aspect, the present invention provides a primer pair for identifying the targeted interference efficiency of the solute-associated carrier 26A3 gene SLC26A3, including: si-SLC26A3-F and si-SLC26A3-R, whose nucleotide sequences are shown in SEQ ID NO.12 and SEQ ID NO.13, respectively.

[0014] In a third aspect, the present invention provides an overexpression vector of the SLC26A3 gene, wherein the nucleotide sequence of the CDS region of the SLC26A3 gene in the overexpression vector is shown in SEQ ID NO.30.

[0015] In a fourth aspect, the present invention provides a primer pair for amplifying the CDS region of the SLC26A3 gene in the above-mentioned SLC26A3 gene overexpression vector, comprising: SLC26A3-CDS-F and SLC26A3-CDS-R, whose nucleotide sequences are SEQ ID NO.31 and SEQ ID NO.32, respectively.

[0016] In a fifth aspect, the present invention provides a method for overexpressing the solute-associated carrier 26A3 gene SLC26A3, wherein the above-mentioned overexpression vector is used to increase the expression level of the solute-associated carrier 26A3 gene SLC26A3 in cells.

[0017] Specifically, the present invention connects the KOZAK strong promoter sequence to the CDS sequence of the solute-related vector 26A3 gene SLC26A3 through PCR amplification, and the amplification primers used are SLC26A3-CDS-KOZAK-F and SLC26A3-CDS-KOZAK-R, and their nucleotide sequences are SEQ ID NO.33 and SEQ ID NO.34; secondly, the PiggyBac vector homology arm sequence is connected to the CDS sequence of the solute-related vector 26A3 gene SLC26A3 carrying the KOZAK strong promoter through PCR amplification, and the amplification primers used are SLC26A3-CDS-KOZAK-TYB-F and SLC26A3-CDS-KOZAK-TYB-R, and their nucleotide sequences are SEQ ID NO.35 and SEQ ID NO.36; Finally, the CDS sequence of the solute-related vector 26A3 gene SLC26A3 carrying the KOZAK strong promoter and the PiggyBac vector homology arm and the linearized PiggyBac vector were co-transfected into the epithelial cell IPEC-J2.

[0018] In a sixth aspect, the present invention provides the use of the above-mentioned small interfering RNA or the above-mentioned overexpression vector in regulating the barrier function of pig intestinal epithelial cells. In the application provided by the present invention, the small interfering RNA is used to interfere with the solute-related carrier 26A3 gene SLC26A3 to weaken the barrier function of intestinal epithelial cells; Cells were transfected with overexpression vectors to enhance the barrier function of intestinal epithelial cells.

[0019] In the application provided by the present invention, MUC2, MUC13, TFF3, OCLN, CLDN3, E-cadherin and SLC15A1 genes are used to detect the integrity of intestinal cell barrier function.

[0020] Specifically, the present invention prepares an overexpression vector for the SLC26A3 gene, transfects porcine small intestinal epithelial cells IPEC-J2, and overexpresses the solute-related vector 26A3 gene SLC26A3. The overexpression vector is transfected into porcine small intestinal epithelial cells IPEC-J2, and the transfection efficiency is evaluated 48 hours later. At the same time, the expression levels of MUC2, MUC13, TFF3, OCLN, CLDN3, E-cadherin and SLC15A1 genes related to the barrier function of intestinal epithelial cells are detected by fluorescent quantitative PCR; and the protein expression levels of MUC2, MUC13 and OCLN are detected by Western Blotting. The results show that the expression of mucin secreted by intestinal epithelial cells and intestinal epithelial cell tight junction proteins are significantly upregulated, which has the effect of enhancing the barrier function of intestinal epithelial cells and can be used for the treatment of impaired barrier function of epithelial cells.

[0021] Specifically, primer pairs are used to detect the expression levels of MUC2, MUC13, TFF3, OCLN, CLDN3, E-cadherin and / or SLC15A1 genes; the primer pair sequences for detecting MUC2 are shown in SEQ ID NO.14 and SEQ ID NO.15, the primer pair sequences for detecting MUC13 are shown in SEQ ID NO.16 and SEQ ID NO.17, the primer pair sequences for detecting TFF3 are shown in SEQ ID NO.18 and SEQ ID NO.19, the primer pair sequences for detecting SLC15A1 are shown in SEQ ID NO.20 and SEQ ID NO.21, the primer pair sequences for detecting OCLN are shown in SEQ ID NO.22 and SEQ ID NO.23, the primer pair sequences for detecting CLDN3 are shown in SEQ ID NO.24 and SEQ ID NO.25, and the primer pair sequences for detecting E-cadherin are shown in SEQ ID NO.26 and SEQ ID NO.27.

[0022] In the application provided by the present invention, mucin MUC2, small peptide transporter TFF3 and SLC15A1, tight junction protein OCLN, and cadherin E-cadherin were significantly downregulated, indicating that the barrier function of intestinal epithelial cells was impaired; mucin MUC2, small peptide transporter SLC15A1, tight junction protein OCLN and CLDN3 were significantly upregulated, indicating that the barrier function of intestinal epithelial cells was enhanced.

[0023] The beneficial effects of the present invention are: The present invention discloses a small interfering RNA, an overexpression vector and its application for regulating the barrier function of intestinal epithelial cells. The present invention provides a method for interfering with and overexpressing the solute-related carrier 26A3 gene SLC26A3 to regulate the barrier function of pig intestinal epithelial cells based on the role of the solute-related carrier 26A3 gene SLC26A3 in the body's acid-base balance, intestinal epithelial barrier, intestinal microbial flora and immune regulation, which may cause and / or aggravate intestinal inflammation, as well as its role as a therapeutic target. Based on the similarities between pigs and humans in anatomy, physiology and genetics, it will lay the foundation for the construction of pig and human IBD models and targeted treatment. In addition, the small interfering RNA with the solute-related carrier 26A3 gene SLC26A3 as the target gene provided by the present invention has a high interference efficiency. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0025] Figure 1 The four small interfering RNAs of the present invention, namely, si-SLC26A3-1, si-SLC26A3-2, si-SLC26A3-3 and si-SLC26A3-4, target the position of the solute-associated carrier 26A3 gene SLC26A3.

[0026] Figure 2 Figure 3 The efficiency of interfering with the solute-associated vector 26A3 gene SLC26A3 after transfection of IPEC-J2 cells with si-NC (negative control) or si-SLC26A3-1, si-SLC26A3-2, si-SLC26A3-3, and si-SLC26A3-4.

[0027] Figure 3 After IPEC-J2 cells were transfected with si-SLC26A3-1 to interfere with the solute-related carrier 26A3 gene SLC26A3, qPCR was used to detect the changes in the expression levels of MUC2, MUC13, TFF3, SLC15A1, OCLN, CLDN3 and E-cadherin.

[0028] Figure 4 After IPEC-J2 cells were transfected with si-SLC26A3-1 to interfere with the solute-related carrier 26A3 gene SLC26A3, the expression changes of MUC2, MUC13 and OCLN were detected at the protein level.

[0029] Figure 5 After IPEC-J2 cells were transfected with the solute-related carrier 26A3 gene SLC26A3 overexpression vector, the luminescence of the transfected cells was observed under a fluorescence microscope.

[0030] Figure 6 After IPEC-J2 cells were transfected with the solute-related carrier 26A3 gene SLC26A3 overexpression vector, the expression changes of SLC26A3 were detected by qPCR.

[0031] Figure 7 After IPEC-J2 cells were transfected with the solute-related carrier 26A3 gene SLC26A3 overexpression vector, the expression changes of SLC26A3 were detected at the protein level.

[0032] Figure 8 After IPEC-J2 cells were transfected with the solute-related carrier 26A3 gene SLC26A3 overexpression vector, qPCR was used to detect the changes in the expression levels of MUC2, MUC13, TFF3, SLC15A1, OCLN, CLDN3 and E-cadherin.

[0033] Fig. 9 After IPEC-J2 cells were transfected with the solute-related carrier 26A3 gene SLC26A3 overexpression vector, the expression changes of MUC2, MUC13 and OCLN were detected at the protein level. DETAILED DESCRIPTION

[0034] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be clearly and completely described below in conjunction with the drawings of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0035] The present invention downloads the nucleotide sequence of the porcine solute-associated vector 26A3 gene SLC26A3 from the NCBI database, designs four small interfering RNA sequences for the complete transcript sequence, transfects porcine small intestinal epithelial cells IPEC-J2, and after interference efficiency evaluation, selects si-SLC26A3-1 to carry out solute-associated vector 26A3 gene SLC26A3 interference and intestinal epithelial cell barrier function impairment evaluation; at the same time, a CDS overexpression vector of the solute-associated vector 26A3 gene SLC26A3 and an evaluation of enhancing the intestinal epithelial cell barrier function are constructed. The present invention is described in detail below using the solute-associated vector 26A3 gene SLC26A3 interference and overexpression designed by the present invention as an example.

[0036] Example 1: Acquisition of siRNA sequences

[0037] The nucleotide sequence of the porcine solute-related carrier 26A3 gene SLC26A3 (SEQ ID NO.1) was downloaded from the NCBI database. A total of four siRNAs were designed targeting the complete transcript sequence, which were named si-SLC26A3-1, si-SLC26A3-2, si-SLC26A3-3, and si-SLC26A3-4, respectively. siNC was used as a negative control. The interfering RNA sequence information is shown in Table 1. The position of the targeted SEQ ID NO.1 sequence is shown in Figure 1 shown.

[0038] Table 1 siRNA sequences targeting SLC26A3

[0039] Example 2: Evaluation of siRNA sequence interference efficiency

[0040] (1) Resuscitate porcine intestinal epithelial cells IPEC-J2 in a 10 cm dish. When the cells are about 80% full, inoculate the cells in a 6-well plate for transfection.

[0041] (2) Transfection steps were as follows: IPEC-J2 cells were transfected with si-NC (negative control) or si-SLC26A3-1, si-SLC26A3-2, si-SLC26A3-3, and si-SLC26A3-4 using Lipofectamine™ RNAiMAX transfection reagent, where siRNA was synthesized by Shanghai Jima Pharmaceutical Co., Ltd.

[0042] (3) After 48 hours of siRNA interference, the IPEC-J2 cells in the 6-well plate that had been interfered with by siRNA were scraped off using a cell scraper, and the RNA and protein of the cells were extracted to detect the interference efficiency of siRNA on the SLC26A3 gene at the mRNA level and protein level.

[0043] (4) The RNA of cells after SLC26A3 gene interference was reverse transcribed using the Takara reverse transcription kit to obtain cDNA. Reverse transcription mainly includes two steps: The first step is to remove the genome, and the system is shown in Table 2: Table 2 Systems used to remove genomes

[0044] Reaction conditions: 42℃ for 2 min.

[0045] Step 2: Use the reaction solution of step 1 for reverse transcription reaction. The specific reaction system is shown in Table 3: Table 3 Reverse transcription reaction system

[0046] Reaction conditions: 37℃ 15 min→85℃ 5 sec→4℃.

[0047] The reverse transcribed cDNA was used as a template for qPCR to detect the interference efficiency of the SLC26A3 gene. The primers were designed by the NCBI online website and synthesized by Shanghai Bio-Tech. The primer sequences used are shown in Table 4, the qPCR system is shown in Table 5, and the mRNA expression level of the SLC26A3 gene was interfered with. Figure 2 The results showed that compared with the normal (si-NC), the mRNA expression levels of the SLC26A3 gene were significantly reduced after interference with si-SLC26A3-1, si-SLC26A3-2, si-SLC26A3-3 and si-SLC26A3-4. Among them, the reduction level of si-SLC26A3-1 was significantly different from that of the other three small interfering RNAs, that is, si-SLC26A3-1 had the highest intervention efficiency on the porcine solute-related carrier 26A3 gene SLC26A3.

[0048] Table 4 qPCR primer list

[0049] Table 5 Fluorescence quantitative PCR system

[0050] Example 3: Evaluation of intestinal epithelial cell barrier function by interfering with SLC26A3

[0051] (1) Resuscitate porcine intestinal epithelial cells IPEC-J2 in a 10 cm dish. When the cells are about 80% full, inoculate the cells in a 6-well plate for transfection. (2) The transfection steps are as follows: IPEC-J2 cells were transfected with si-NC (negative control) or si-SLC26A3-1 using Lipofectamine™ RNAiMAX transfection reagent, where siRNA was synthesized by Shanghai Jima Pharmaceutical Co., Ltd.

[0052] (3) 48 hours after siRNA interference, the IPEC-J2 cells in the 6-well plate after siRNA interference were scraped with a cell scraper, and the RNA and protein of the cells were extracted to evaluate the integrity of the intestinal epithelial cell barrier function at the mRNA level and protein level.

[0053] (4) The RNA of cells after SLC26A3 gene interference was reverse transcribed using the Takara reverse transcription kit to obtain cDNA. Reverse transcription mainly includes two steps: Step 1: Removal of genome, the system is shown in Table 2, reaction conditions: 42°C 2 min.

[0054] Step 2: Use the reaction solution of step 1 for reverse transcription reaction. The specific reaction system is shown in Table 3. The reaction conditions are: 37°C 15 min→85°C 5 sec→4°C.

[0055] The reverse transcribed cDNA was used as a template for qPCR to detect MUC2, MUC13, TFF3, SLC15A1, OCLN, CLDN3 and E-cadherin, with 18S as the internal reference gene. The primers were designed by the NCBI online website and synthesized by Shanghai Bio-Tech. The primer sequences used are shown in Table 6, the qPCR system is shown in Table 5, and the mRNA expression level of the SLC26A3 gene is shown in Table 6. Figure 3 The results showed that after si-SLC26A3-1 interfered with the porcine solute-associated carrier 26A3 gene, the expression of mucin MUC2, small peptide transporters TFF3 and SLC15A1, and tight junction protein OCLN secreted by intestinal epithelial cells was significantly downregulated, indicating that its barrier function was impaired.

[0056]

[0057] (5) The extracted cell proteins were denatured and the expression of MUC2, MUC13 and OCLN proteins was detected by SDS-PAGE test, with GAPDH as the control. The relevant protein antibodies MUC2 (Abcam, Cat#ab272692, 1:1000); MUC13 (Abcam, Cat#ab235450, 1:1000), OCLN (CST, Cat#91131, 1:1000), GAPDH (CellSignaling Technology, Cat#5174, 1:000) were used to detect the protein expression level. The protein expression level of the SLC26A3 gene was interfered with. Figure 4 As shown, the results showed that the expression of MUC2 and OCLN was reduced and the barrier function of intestinal epithelial cells was impaired.

[0058] Example 4: Evaluation of barrier function of intestinal epithelial cells overexpressing SLC26A3

[0059] (1) Amplification of the CDS region of the SLC26A3 gene

[0060] The CDS region of the SLC26A3 gene was amplified using KOD high-fidelity enzyme, the amplification system is shown in Table 5, the total amplified length is 2280 bp, the nucleotide sequence is SEQ ID NO.30, and the primer SLC26A3-CDS sequence is shown in Table 7. The amplified product was used as a template, and the KOZAK strong promoter and vector homology arms were added to both ends of the primers. The primer sequences were SLC26A3-CDS-KOZAK and SLC26A3-CDS-KOZAK-TYB, respectively, as shown in Table 7, and the amplification system was shown in Table 8.

[0061]

[0062] Table 8 CDS region amplification system

[0063] (2) PiggyBac vector linearization

[0064] The PiggyBac circular vector with GFP selection marker was linearized by enzyme digestion with PmeⅠ and KpnⅠ, and the digestion was carried out at 37°C for 2h. The digestion product was recovered and purified by gel, and the concentration was determined before use. The digestion system is shown in Table 9.

[0065] Table 9 PiggyBac vector linearization system

[0066] (3) Construction of SLC26A3 gene overexpression vector

[0067] The CDS region of the porcine solute-related vector 26A3 gene SLC26A3 amplified by SLC26A3-CDS-KOZAK-TYB was homologously recombined with the linearized PiggyBac using the Novizan seamless cloning kit, and the seamless cloning system is shown in Table 10. The recombinant fragment was transformed into DH5α competent cells and cultured on solid LB medium containing Amp. After the colonies grew, a single colony was picked and shaken to send to the company for sequencing and identification. The successfully connected plasmid was expanded and used for subsequent transfection experiments.

[0068] Table 10 Homologous recombination system

[0069] (4) Construction of IPEC-J2 cell model with overexpression of SLC26A3 gene

[0070] 1) Resuscitate porcine intestinal epithelial cells IPEC-J2 in a 10 cm dish. When the cells grow to about 80%, in order to obtain cells overexpressing the SLC26A3 gene, co-transfect the cells with 5 µg of the PiggyBac reconstructed vector and 4PB auxiliary vector that were successfully sequenced in the CDS region of the SLC26A3 gene; 2) Electroporate 106 cells / well. Use Lonza kit. The ratio of Solution and Supplement is 82:18. Mix them thoroughly. The cell electroporate procedure is T020. 3) After transfection, the cells were cultured in DMEM complete medium and the luminescence was observed under a fluorescence microscope after 48 h. DMEM medium containing puromycin (2 μg / mL) was used for drug screening for 12 h and the luminescence of the transfected cells was observed under a fluorescence microscope. Figure 5 shown.

[0071] (5) Detection of SLC26A3 overexpression efficiency

[0072] After scraping the IPEC-J2 cells overexpressing the SLC26A3 gene in the 6-well plate using a cell scraper, the RNA and protein of the cells were extracted to detect the overexpression efficiency of the SLC26A3 gene at the mRNA and protein levels. The primer sequences used are shown in Table 4, the qPCR system is shown in Table 5, and the mRNA expression level of the overexpressed SLC26A3 gene is shown in Table 5. Figure 6 As shown, the results showed that SLC26A3 expression was significantly upregulated; SLC26A3 antibody (My Biosource, Cat# MBS3200515) was used to detect protein expression levels, and the results were as follows Figure 7 As shown, it indicated that SLC26A3 expression was significantly upregulated.

[0073] (6) Evaluation of the barrier function of intestinal epithelial cells overexpressing SLC26A3

[0074] qPCR was performed using the reverse transcribed cDNA as a template to detect MUC2, MUC13, TFF3, SLC15A1, OCLN, CLDN3 and E-cadherin, with 18S as the internal reference gene. Primers were designed by the NCBI online website and synthesized by Shanghai Bio-Tech. The primer sequences used are shown in Table 6, and the qPCR system is shown in Table 5. The results showed that after overexpression of the porcine solute-associated carrier 26A3 gene, the mucin MUC2, small peptide transporter SLC15A1, tight junction protein OCLN and CLDN3 secreted by intestinal epithelial cells were significantly upregulated, indicating that their barrier function was enhanced ( Figure 8 ).

[0075] (7) The extracted cell proteins were denatured and the expression of MUC2, MUC13 and OCLN proteins was detected by SDS-PAGE test, with GAPDH as the control. The relevant protein antibodies MUC2 (Abcam, Cat#ab272692, 1:1000); MUC13 (Abcam, Cat#ab235450, 1:1000), OCLN (CST, Cat#91131, 1:1000), GAPDH (CellSignaling Technology, Cat#5174, 1:000) were used to detect the protein expression level. The results showed that the expression of MUC2, MUC13 and OCLN was significantly upregulated, and the barrier function of intestinal epithelial cells was enhanced ( Fig. 9 ).

[0076] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A small interfering RNA targeting the solute-related carrier 26A3 gene SLC26A3, characterized in that: The small interfering RNA is named si-SLC26A3-1, and the nucleotide sequence of the si-SLC26A3-1 is shown in SEQ ID NO.4 and SEQ ID NO.

5.

2. The small interfering RNA according to claim 1, characterized in that The target gene of the small interfering RNA is the solute-related carrier 26A3 gene SLC26A3, and the nucleotide sequence of the target gene is shown in SEQ ID NO.

1.

3. Primer pairs for identification of targeted interference efficiency of solute-related carrier 26A3 gene SLC26A3, including: The nucleotide sequences of si-SLC26A3-F and si-SLC26A3-R are shown in SEQ ID NO.12 and SEQ ID NO.13, respectively.

4. A SLC26A3 gene overexpression vector, characterized in that: The nucleotide sequence of the CDS region of the SLC26A3 gene in the overexpression vector is shown in SEQ ID NO.

30.

5. A primer pair for amplifying the CDS region of the SLC26A3 gene in the overexpression vector of the SLC26A3 gene according to claim 4, characterized in that: include: The nucleotide sequences of SLC26A3-CDS-F and SLC26A3-CDS-R are SEQ ID NO.31 and SEQ ID NO.32, respectively.

6. A method for overexpressing the solute-related carrier 26A3 gene SLC26A3, characterized in that: In the method, the overexpression vector according to claim 4 is used to increase the expression level of the solute-related carrier 26A3 gene SLC26A3 in the cell.

7. Use of the small interfering RNA according to claim 1 or the overexpression vector according to claim 4 in regulating the barrier function of pig intestinal epithelial cells; using small interfering RNA to interfere with the solute-related carrier 26A3 gene SLC26A3 to weaken the barrier function of intestinal epithelial cells; Cells were transfected with overexpression vectors to enhance the barrier function of intestinal epithelial cells.

8. The use according to claim 7, characterized in that: The integrity of intestinal cell barrier function was detected using MUC2, MUC13, TFF3, OCLN, CLDN3, E-cadherin and SLC15A1 genes.

9. The use according to claim 8, characterized in that: Primer pairs are used to detect the expression levels of MUC2, MUC13, TFF3, OCLN, CLDN3, E-cadherin and / or SLC15A1 genes; the primer pair sequences for detecting MUC2 are shown in SEQ ID NO.14 and SEQ ID NO.15, the primer pair sequences for detecting MUC13 are shown in SEQ ID NO.16 and SEQ ID NO.17, the primer pair sequences for detecting TFF3 are shown in SEQ ID NO.18 and SEQ ID NO.19, the primer pair sequences for detecting SLC15A1 are shown in SEQ ID NO.20 and SEQ ID NO.21, the primer pair sequences for detecting OCLN are shown in SEQ ID NO.22 and SEQ ID NO.23, the primer pair sequences for detecting CLDN3 are shown in SEQ ID NO.24 and SEQ ID NO.25, and the primer pair sequences for detecting E-cadherin are shown in SEQ ID NO.26 and SEQ ID NO.

27.

10. The use according to claim 9, characterized in that: Mucin MUC2, small peptide transporters TFF3 and SLC15A1, tight junction protein OCLN, and cadherin E-cadherin were significantly downregulated, indicating that the barrier function of intestinal epithelial cells was impaired; mucin MUC2, small peptide transporter SLC15A1, tight junction protein OCLN and CLDN3 were significantly upregulated, indicating that the barrier function of intestinal epithelial cells was enhanced.

Citation Information

Cited By

  • SiRNA of targeted ADAM17 gene based on intestinal barrier repair and application of siRNA in improvement of IBS visceral hypersensitivity

    CN122104709A